NCT07149454View on ClinicalTrials.gov

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Anti-Tetanus Toxin Monoclonal Antibody Injection

PHASE1Enrolling by invitationINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

August 18, 2025

Primary Completion Date

May 27, 2026

Study Completion Date

June 24, 2026

Conditions
Tetanus
Interventions
DRUG

Recombinant Human Anti-Tetanus Toxin Monoclonal Antibody Injection

intramuscular injection

DRUG

Human Tetanus Immunoglobulin

intramuscular injection

DRUG

Placebo

intramuscular injection

Trial Locations (1)

730000

Lanzhou Institute of Biological Products Co., Ltd., Lanzhou

All Listed Sponsors
lead

Lanzhou Institute of Biological Products Co., Ltd

INDUSTRY